Search Results for "diagnosis"

Virtual interactive clinic offers quarterly 1-hour sessions focused on AL (light chain) and ATTR (transthyretin) amyloidosis, two underrecognized but increasingly manageable causes of heart failure and multisystem disease.

This deck highlights diagnostic and staging tools for assessing patients with ATTR.

Standard response letter on the use of givosiran in patients with a prior history of hemin prophylaxis from the ENVISION study.

ATTR-CM HELIOS-B Data Summary deck provides a comprehensive overview of the HELIOS-B results. Also includes information on ATTR-CM and the MOA of RNAi therapeutics.

Title: Symptoms and Disease Burden of ATTR External description: This slide deck provides an overview of the symptoms and disease burden of ATTR.

Infographic companion to the article by Sato et al, "Neurofilament light chain as a biomarker for monitoring response to change in treatment in hereditary ATTR amyloidosis", published in the journal Amyloid, 2023.

Standard response letter on givosiran and pediatric use. This medical information response contains clinical data from the ENVISION study, ELEVATE registry, and published case reports.

Standard response letter on the use of givosiran in patients with pre-existing renal impairment.

Standard response letter on givosiran and monitoring post-injection.

Standard response letter on lumasiran and dialysis. This medical information response contains clinical data from the ILLUMINATE-C study and published case reports.

Standard response letter on the use of givosiran in patients with AHP without an identified porphyria-related genetic mutation.

Standard response letter on givosiran and the adverse event of pancreatitis.

An infographic depicting a post-hoc analysis of the ENVISION phase 3 study to understand the long-term clinical outcomes of patients who were not attack free after 6-months of givosiran treatment.

Standard response letter on patisiran and the open-label phase 3b study evaluating the efficacy, safety and PK of patisiran in patients with hATTR who had polyneuropathy progression post-OLT. Additional summaries of case reports are also included.

Standard response letter on the use of lumasiran in patients who have had an isolated kidney transplant.

Standard response letter on patisiran and the APOLLO study, a phase 3 study evaluating the efficacy and safety of patisiran in patients with the hATTR-PN.

This material is a short summary of HELIOS-B primary medical and scientific publications (including peer-reviewed medical journal articles and scientific conference presentations)

Standard response letter on the lumasiran phase 3 clinical study ILLUMINATE-B, a study evaluating the efficacy and safety of lumasiran in infants and children less than 6 years old with PH1.

This handout provides an overview of two diagnostic algorithms for ATTR amyloidosis in patients with carpal tunnel syndrome.

This infographic discusses the study design, objectives, key patient criteria, and planned countries for the BONAPH1DE observational study.

This slide deck highlights the Phase 3 trial design for HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy.